SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Germany · Delayed Price · Currency is EUR 26.25
+0.35 (1.35%)
At close: Jul 16, 2025, 5:30 PM CET
ETR:1SXP Income Statement
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 |
| 972.81 | 957.09 | 898.6 | 821.14 | 648.67 | 584.23 | |
Revenue Growth (YoY) | 6.16% | 6.51% | 9.43% | 26.59% | 11.03% | - |
Cost of Revenue | 652.74 | 634.48 | 582.11 | 524.51 | 422.5 | 388.22 |
Gross Profit | 320.07 | 322.61 | 316.49 | 296.64 | 226.17 | 196.01 |
Selling, General & Admin | 127.9 | 125.18 | 122.68 | 110.78 | 92.5 | 89.63 |
Research & Development | 25.36 | 24.25 | 26.82 | 23.53 | 22.29 | 23.58 |
Other Operating Expenses | -13.46 | -15.67 | -4.23 | -5.68 | -3.12 | -8.18 |
Operating Expenses | 139.8 | 133.77 | 145.28 | 128.63 | 111.67 | 105.04 |
Operating Income | 180.27 | 188.84 | 171.21 | 168.01 | 114.5 | 90.97 |
Interest Expense | -16.95 | -12.78 | -6.66 | -2.11 | -1.19 | -1.51 |
Interest & Investment Income | 8.19 | 5.96 | 5.23 | 2.14 | 0.56 | 0.56 |
Earnings From Equity Investments | 13.95 | 12.49 | 11.74 | 12.99 | 13.7 | 5.55 |
Currency Exchange Gain (Loss) | 1.82 | -11.09 | 2.71 | -7.03 | -1.45 | 0.45 |
Other Non Operating Income (Expenses) | -1.13 | -1.08 | -4.55 | -5.54 | -3.26 | -1.55 |
EBT Excluding Unusual Items | 186.15 | 182.35 | 179.68 | 168.46 | 122.87 | 94.46 |
Merger & Restructuring Charges | - | - | - | -11.78 | - | - |
Gain (Loss) on Sale of Assets | 0.59 | 0.59 | 0.39 | 1.51 | 0.3 | 0.72 |
Asset Writedown | - | - | 5.2 | - | - | - |
Pretax Income | 187.78 | 183.97 | 185.8 | 158.29 | 123.28 | 95.3 |
Income Tax Expense | 39.57 | 33.63 | 33.87 | 32.44 | 22.12 | 17.67 |
Earnings From Continuing Operations | 148.21 | 150.35 | 151.93 | 125.85 | 101.17 | 77.63 |
Minority Interest in Earnings | -0.64 | -0.66 | -0.09 | -0.47 | -0.41 | -0.15 |
Net Income | 147.57 | 149.69 | 151.84 | 125.38 | 100.75 | 77.48 |
Net Income to Common | 147.57 | 149.69 | 151.84 | 125.38 | 100.75 | 77.48 |
Net Income Growth | 9.61% | -1.42% | 21.11% | 24.44% | 30.04% | - |
Shares Outstanding (Basic) | 150 | 151 | 151 | 151 | 151 | 151 |
Shares Outstanding (Diluted) | 150 | 151 | 151 | 151 | 151 | 151 |
Shares Change (YoY) | -0.96% | - | - | - | - | - |
EPS (Basic) | 0.98 | 0.99 | 1.01 | 0.83 | 0.67 | 0.51 |
EPS (Diluted) | 0.98 | 0.99 | 1.01 | 0.83 | 0.67 | 0.51 |
EPS Growth | 10.24% | -1.80% | 21.46% | 24.08% | 31.17% | - |
Free Cash Flow | 117.88 | 80.25 | 6.19 | 30.11 | 34.14 | 19.22 |
Free Cash Flow Per Share | 0.79 | 0.53 | 0.04 | 0.20 | 0.23 | 0.13 |
Dividend Per Share | 0.160 | 0.160 | 0.150 | 0.125 | - | - |
Dividend Growth | 6.67% | 6.67% | 20.00% | - | - | - |
Gross Margin | 32.90% | 33.71% | 35.22% | 36.13% | 34.87% | 33.55% |
Operating Margin | 18.53% | 19.73% | 19.05% | 20.46% | 17.65% | 15.57% |
Profit Margin | 15.17% | 15.64% | 16.90% | 15.27% | 15.53% | 13.26% |
Free Cash Flow Margin | 12.12% | 8.38% | 0.69% | 3.67% | 5.26% | 3.29% |
EBITDA | 247.58 | 249 | 217.5 | 211.8 | 150.94 | 124.7 |
EBITDA Margin | 25.45% | 26.02% | 24.20% | 25.79% | 23.27% | 21.34% |
D&A For EBITDA | 67.3 | 60.16 | 46.29 | 43.79 | 36.44 | 33.73 |
EBIT | 180.27 | 188.84 | 171.21 | 168.01 | 114.5 | 90.97 |
EBIT Margin | 18.53% | 19.73% | 19.05% | 20.46% | 17.65% | 15.57% |
Effective Tax Rate | 21.07% | 18.28% | 18.23% | 20.49% | 17.94% | 18.54% |
Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.